TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body weight 40 to 136 kg (88 to 300 lbs)~* Recent history of GERD related symptoms (at least twice weekly) confirmed during screening.~* Recent history of 8 week PPI treatment without significant improvement~* Abnormal bilirubin level as assessed by Bilitec~* Normal esophageal pH value (pH\<4.0 for \<4.2% of the time calculated over a 24 hour period)~* Platelet count (thrombocytes) \>100,000/µL~* Normal Hgb and Hct levels~* Able and willing to comply with all protocol procedures for the planned duration of the study~* Able and willing to understand, sign and date an informed consent document, and authorize access to protected health information.~* Females must be postmenopausal, surgically incapable of bearing children, or practicing a reliable method of birth control (hormonal contraceptives, intrauterine devices, spermicide and barrier). Partner/spouse sterility may also qualify at the Investigator's discretion. Females of child-bearing potential must have a negative urine pregnancy test at baseline.~Exclusion Criteria:~* Concurrent GI or other pathology which could interfere with the course of the study (e.g., erosive esophagitis, malabsorption, cirrhosis, ascites, bleeding ulcer, diabetes, scleroderma, non-GI myopathy or neuropathy etc.) Note: patients with Barrett's esophagus (short segment defined as \< 3 cm) can be included.~* Patients with cancer or undergoing chemotherapy for the treatment of cancer~* Patients with a history of upper GI surgery~* Patients with GERD complications such as stricture of the esophagus~* Contraindication to continued PPI treatment~* Patients requiring the concomitant use of NSAIDs for the duration of the study~* Uncontrolled systemic disease~* Diagnosis of a psychiatric disorder within the past 2 years and not on a stable dose of medications for at least 6 months~* Other major physical or psychiatric illness in previous 6 months as determined by the treating physician~* Known hypersensitivity or contraindication to any component of the test product (study drug) or diagnostics used~* Participation in another study within eight (8) weeks prior to randomization~* Unable to attend all visits required by the protocol~* Pregnant, breast feeding, or planning to become pregnant during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AST-120, 2 gram sachets
- 2 (Type: PLACEBO_COMPARATOR): Celphere CP-305, stained to match appearance of AST-120 in 2g sachets.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bioenergy, Depression, Anxiety and Stress After Liver Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~(i) liver transplant recipient (ii) must be able to use immunosuppressive agents (iii) 18 years or older Liver transplant recipients~Exclusion Criteria:~having psychiatric problems having language and communication problems

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: NO_INTERVENTION): No intervention: This group includes liver transplant recipients and no intervention is applied to this group. Depression, anxiety and stress levels are measured in the pre-test. No intervention is implemented. As a post-test, depression, anxiety and stress levels are measured again.
- 2 (Type: EXPERIMENTAL): Bioenergy group: This group includes liver transplant recipients and recipients who underwent intervention. Depression, anxiety and stress levels are measured in the pre-test. Bioenergy is then applied. As a post-test, depression, anxiety and stress levels are measured again.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is at least 18 and no older than 75 years of age at the time of screening~* Patient has a diagnosis of cancer~* Patient has moderate to severe pain that is related to cancer or its treatment and is expected to last indefinitely and is currently taking an around-the-clock opioid to treat his/her pain~* Patient is already receiving opioid therapy, has demonstrated opioid tolerance~* A responsible adult caregiver is available in the event of an emergency at home~Exclusion Criteria:~* Patient has uncontrolled or rapidly escalating pain as determined by the investigator~* Patient has a history of substance abuse or has a substance abuse disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ZR-02-01 (Type: EXPERIMENTAL): ZR-02-01 matrix transdermal fentanyl patch

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of IMN1207 Versus Casein on Weight Loss, Survival and Quality of Life in Non-small Cell Lung Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non small cell lung cancer stage III or stage IV.~* Karnofsky performance status greater or equal to 70%.~* Expected participation in study for more than 3 months.~* Involuntary decrease in body weight of more than 3% over the 1-5 months period immediately preceding study entry.~* Age 18 or older.~* Serum creatine less or equal to 3.0mg/dL or 265 µmol/L.~* Total bilirubin in the normal range (0.2-1.2 mg/dL) SGPT equal to or less than 4 times the upper limit of normal.~* Reliable contraception (ovariectomy, hysterectomy, tubuligation for at least six months, oral contraceptive, barrier method, etc.) for women of child bearing potential.~Exclusion Criteria:~* History of angioedema or allergic reactions to any compound employed in this study.~* Pregnancy and lactating.~* Uncontrolled metastatic brain tumors.~* Milk protein intolerance.~* Subjects currently using N-acetylcysteine, alpha-lipoic acid supplements, or dry whey protein supplements.~* Presence of ascitis or edema according to principle investigator's clinical judgment.~* Significant anemia, as defined by the requirement of treatment with EPO.~* Subjects with either mild or soy allergy/intolerance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IMN1207 (Type: EXPERIMENTAL): Dietary Supplement: IMN1207~Stratum A: CRP \<40 mg/L and WBC \< 11x109/L (i.e. subjects with relatively low levels of inflammation).~Stratum B: CRP ≥ 40 mg/L and/or WBC ≥ 11x109/L (i.e. subjects with relatively high levels of inflammation.
- Casein (Type: PLACEBO_COMPARATOR): Dietary Supplement: Casein.~Stratum A: CRP \<40 mg/L and WBC \< 11x109/L (i.e. subjects with relatively low levels of inflammation).~Stratum B: CRP ≥ 40 mg/L and/or WBC ≥ 11x109/L (i.e. subjects with relatively high levels of inflammation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intrathecal Magnesium for Same-day-surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Same day surgery patients~* Operated in lithotomy or arthroscopy position or obese patients~Exclusion Criteria:~* American Society of Anesthesia 3 or 4 patients~* Younger than 18 or elder than 80 years-old~* Active lumbar pain~* Any short of chronic neurologic disease~* Any short of myopathy~* Pregnant women~* Previous history of allergic or toxic reaction to lidocaine, magnesium or fentanyl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Intrathecal magnesium (Type: EXPERIMENTAL): Intrathecal magnesium sulfate 15% 0,5 mL (75 mg) is added to lidocaine 5% 1 mL (50 mg)as anesthetic adjuvant
- Intrathecal fentanyl (Type: ACTIVE_COMPARATOR): Intrathecal fentanyl 0.5 mL (25 micrograms)is added to lidocaine 5% 1 ML (50 mg) as anesthetic adjuvant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Below Knee DVT Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over the age of 18 admitted to a trauma or general surgery service will be eligible~* Patients diagnosed with an isolated distal DVT~* Able to obtain informed consent~Exclusion Criteria:~* Patients with a previous diagnosis of hypercoagulability~* Patients on chronic anticoagulation~* Patients with a history of heparin induced thrombocytopenia~* Patients have preexisting contraindications to anticoagulation~* Patients in renal failure requiring adjusted enoxaparin dosing~* Pregnant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Dose Enoxaparin (Type: ACTIVE_COMPARATOR): Subjects are randomized to receive or begin prophylactic dosing (30 mg BID) of enoxaparin for 6 weeks or until DVT resolution.
- High Dose Enoxaparin (Type: ACTIVE_COMPARATOR): Subjects are randomized to begin therapeutic dosing (1 mg/kg body weight BID) of enoxaparin for 6 weeks or until DVT resolution.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Chronic Obstructive Pulmonary Disease (COPD) Co-Pilot AIR Substudy of CLN0014

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Participant has read, understood, and signed a CLN0020 informed consent form prior to enrollment.~2. Participant is appropriate for Coil treatment per the Conformité Européene (European Conformity \[CE\])-Mark Approved RePneu Instructions for Use (IFU).~3. Participant has been enrolled in and scheduled for treatment(s) with the PneumRx Endobronchial Coil procedure in the CLN0014 study.~4. Participant's PneumRx Endobronchial Coil procedure is scheduled to occur no fewer than 14 days from enrollment, providing enough time to establish a baseline of their daily symptoms. Ten days minimum of baseline data are required, which is defined as the Run-in period going forward.~5. Participant is willing and able to use a smart phone.~Exclusion Criteria:~1. Participant has undergone a Coil procedure.~2. Participant has had an acute exacerbation of COPD that required hospitalization or emergency room visit or treatment with systemic steroids and/or antibiotics during the 28 days prior to CLN0020 enrollment.~3. Participant has a COPD exacerbation or respiratory illness during the Run-in period that in the judgment of the investigator requires medical intervention (for example, treatment with systemic steroids and/or antibiotics and/or hospitalization).~4. Participant is suffering from terminal illness expected to adversely affect survival in the next 12 months.~5. Participant has a history of non-compliance with medical therapies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial to Evaluate the Safety and Efficacy of Acetaminophen in Preterm Infants Used in Combination With Ibuprofen for Closure of the Ductus Arteriosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Preterm infant ≤27 6/7~2. Written parental consent is obtained~3. Infant requires respiratory support~4. diagnosis of a persistent patent ductus arteriosus after 5 days of age, (defined as at least two of the following:~   1. Ductus size ≥ 1.5 mm~  2. Maximum flow velocity through the ductus ≤ 2 m/s~  3. Left atrium to aorta ratio ≥ 1.4~  4. Wide pulse pressure~  5. B-type natriuretic peptide (BNP)~5. Attending neonatologist made decision to treat patent ductus arteriosus~Exclusion Criteria:~1. No parental consent~2. Infants \> 21days of postnatal age~3. Congenital anomalies such as cardiac or multiple anomalies~4. Infection (e.g., septicemia, pneumonia)~5. Bleeding disorder or platelet count\< 50,000/ml~6. Acute kidney injury (AKI)defined as oliguria (urine output\< 0.5 ml/kg/hr for 16hrs) and/or serum creatinine \> 1.5 mg/dl~7. Elevated liver enzymes (\>2 fold from upper normal limits)~8. Pulmonary hypertension or right to left shunt through the ductus arteriosus~9. Diagnosis of necrotizing enterocolitis~10. Unable to tolerate oral medications at the time of enrollment.

- Gender: ALL
- Minimum Age: 5 Days
- Maximum Age: 21 Days
- Healthy Volunteers: f

Study Arms:
- ibuprofen and acetaminophen arm (intervention arm) (Type: EXPERIMENTAL): ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants \> 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Acetaminophen will be administered as oral formulation. Acetaminophen is given at a dose of 15 mg/Kg/dose, q 6 hours, for 3 days (total of 12 doses).
- ibuprofen and placebo arm (control arm) (Type: ACTIVE_COMPARATOR): ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants \> 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Placebo will be sterile water, with similar volume and color as acetaminophen, will be given through the oro-gastric tube, for three days at 6 h intervals.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients with measurable, metastatic or locally advanced hepatocellular carcinoma~2. The diagnosis of HCC should be established either by cyto/histology~3. Patients must be \> 20 years of age.~4. ECOG score \< 2.~5. Signed informed consent.~6. Female patients at child-bearing age must have negative pregnancy test.~Exclusion Criteria:~1. Patients with other systemic diseases which require concurrent usage of glucocorticosteroid or immunosuppressant agent(s) are not eligible.~2. Patients with advanced second primary malignancy are not eligible.~3. Patients with active infection are not eligible.~4. Patients with pregnancy or breast-feeding are not eligible.~5. Patients with brain metastases are not eligible.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acute Pudendal Nerve Stimulation On Leak Point Pressure In Women Urodynamic Early Feasibility Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women between the ages of 18 and 85 years old, inclusive.~* Implanted with a neurostimulation device for at least 3 months prior to consent (Medtronic Interstim neurostimulator models 3023, 3058, 97810, or similar).~* Implanted with a tined lead that is placed and functionable at the pudendal nerve (Medtronic model 3889 or similar).~* Is capable of understanding clinical study procedures and giving informed consent.~* Willing and able to visit the clinic for the UDT evaluation (study procedure)~Exclusion Criteria:~* Medically unstable at time of study and unsafe to undergo urodynamic testing as determined by the investigator.~* History of bladder cancer.~* History of pelvic radiotherapy.~* Active gross hematuria.~* Active symptomatic urinary tract infection (UTI)~* Active symptomatic uncontrolled bladder instability as determined by the investigator.~* History or symptoms of cystocele, enterocele, or rectocele of grade 3 or 4. Per the medical record or as determined by the investigator.~* Presence of an artificial urinary sphincter.~* Women who are pregnant and/or have given birth in the previous 12 months~* Any medical condition that would interfere with the patient's ability to comply with the protocol and/or may affect the outcome of this study or safety of the subject as determined by the investigator~* BMI greater than 39.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Urodynamic testing with and without pudendal nerve stimulation (Type: OTHER): The neuromodulation settings of the implanted device will be adjusted to deliver acute simulation. Urodynamic testing (UDT) will be completed by filling the bladder and observing for urinary leakage. The assessment will be completed with the stimulation sets turned off and then turned on. At the end of the UDT the settings will be returned to the previously set therapeutic values. The neuromodulation settings constitute the dose and can include the voltage/current amplitude, frequency, pulse width, on time/off time duration and electrode polarity assignments. These parameters are limited by the available ranges of the approved neurostimulation device and will be adjusted during the study by the principal investigator to stay within the safe and comfortable levels for each individual study subject.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: An Open Study to Evaluate Whether Pack Size Affects Compliance of Metformin Treatment in Subjects With Type II Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females of age \>=18 years~* Diagnosis of type II diabetes~* HbA1c value no higher than 9.0%~* Evidence of physician-supplied prescription for metformin use~* Stable dose of metformin for 3 months prior to enrolment~* Written informed consent from the subject~Exclusion Criteria:~* Current use of any anti-diabetic medication other than metformin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metformin Small Pack Arm (Type: EXPERIMENTAL): All subjects in the study will be initially followed for an 8-week observational phase during which subjects will visit the pharmacy and purchase metformin following their usual routines. After 8-weeks subjects will be randomised to one of the 2 treatments arms. Subjects in the metformin small pack arm will receive medication free of charge in a small pack. Dosing of metformin will not be dictated by the protocol. Subjects will remain on their prescribed dose of metformin throughout the study, unless a change is recommended by their physician.
- Metformin Large Pack Arm (Type: EXPERIMENTAL): All subjects in the study will be initially followed for an 8-week observational phase during which subjects will visit the pharmacy and purchase metformin following their usual routines. After 8-weeks subjects will be randomised to one of the 2 treatments arms. Subjects in the metformin large pack arm will receive medication free of charge in a large, monthly pack. Dosing of metformin will not be dictated by the protocol. Subjects will remain on their prescribed dose of metformin throughout the study, unless a change is recommended by their physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility